Association between the Pharmacokinetic Parameters of Ganciclovir and Clinical Efficacy and Safety in the Treatment of Cytomegalovirus Infection
Abstract
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in immunocompromised patients. While ganciclovir (GCV) is commonly used for its management, pharmacokinetic (PK) targets for optimal efficacy and minimal toxicity remain controversial. This study aimed to explore the association of PK parameters with the efficacy and safety of GCV in the treatment of CMV infection. We conducted a prospective study of adult patients who received intravenous GCV for CMV infection. Treatment efficacy was defined as a ≥50% reduction in CMV antigen-positive cells using a pp65 antigenemia test. The highest or lowest hematological, hepatic, and renal laboratory values were used to assess safety. Individual PK parameters (area under the concentration–time curve [AUC]24h, trough [Cmin], and peak [Cmax]) plasma concentration were estimated using multiple GCV plasma concentrations from each patient. Associations between PK parameters and efficacy/safety were assessed. Of 23 patients, 20 (87.0%) exhibited an effective response. Median estimated AUC24h, Cmin, and Cmax values were 45.5 mg·h/L, 0.5 mg/L, and 6.8 mg/L, respectively. AUC24h and Cmin were not significantly associated with the efficacy of GCV (odds ratio [OR] 1.05, 95% confidence interval [CI] 0.96–1.16, p = 0.301; OR 0.92, 95% CI 0.11–7.86, p = 0.942). Cmax showed a relatively large but nonsignificant OR (OR 2.45, 95% CI 0.84–7.09, p = 0.099). No clinically relevant associations between PK parameters and safety were observed. Baseline laboratory values were associated with safety. In conclusion, no statistically significant associations were identified between GCV PK parameters and the treatment efficacy/safety of CMV infection in adult patients.
Related
- Acyclovir and ganciclovir exposure and short-term outcomes in hospitalized children with EBV-associated mononucleosis-like illness: a retrospective cohort study using inverse probability of treatment weighting
- Recurrent Ischemic Stroke Despite Dabigatran Therapy: Unexpectedly Low Anti-IIa Activity Revealing Pharmacokinetic Treatment Failure.
- Pharmacokinetic determinants, clinical efficacy, and safety of teicoplanin in adults: a correlative analysis of plasma concentration and treatment outcomes
- Genetic variants involved in sperm motility and their association with sperm motility parameters and risk of male infertility: a systematic review and meta-analysis protocol
- Association of Complete Blood Count Parameters and Systemic Inflammatory Indices with Early Surfactant Administration in Preterm Infants
BibTeX
@article{roongpairoj2026association,
title = {{Association between the Pharmacokinetic Parameters of Ganciclovir and Clinical Efficacy and Safety in the Treatment of Cytomegalovirus Infection}},
author = {Yanika Roongpairoj and Masashi Uchida and Shingo Yamazaki and Yoshihito Ozawa and Yuri Goto and Shunsuke Furuta and Masayuki Ishikawa and Takaaki Suzuki and Emiko Sakaida and Itsuko Ishii},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = aug,
doi = {10.1248/bpb.b26-00209},
url = {https://www.jstage.jst.go.jp/article/bpb/49/8/49_b26-00209/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Association between the Pharmacokinetic Parameters of Ganciclovir and Clinical Efficacy and Safety in the Treatment of Cytomegalovirus Infection
AU - Yanika Roongpairoj
AU - Masashi Uchida
AU - Shingo Yamazaki
AU - Yoshihito Ozawa
AU - Yuri Goto
AU - Shunsuke Furuta
AU - Masayuki Ishikawa
AU - Takaaki Suzuki
AU - Emiko Sakaida
AU - Itsuko Ishii
PY - 2026
DA - 2026/08/22
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00209
UR - https://www.jstage.jst.go.jp/article/bpb/49/8/49_b26-00209/_article
AB - Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in immunocompromised patients. While ganciclovir (GCV) is commonly used for its management, pharmacokinetic (PK) targets for optimal efficacy and minimal toxicity remain controversial. This study aimed to explore the association of PK parameters with the efficacy and safety of GCV in the treatment of CMV infection. We conducted a prospective study of adult patients who received intravenous GCV for CMV infection. Treatment efficacy was defined as a ≥50% reduction in CMV antigen-positive cells using a pp65 antigenemia test. The highest or lowest hematological, hepatic, and renal laboratory values were used to assess safety. Individual PK parameters (area under the concentration–time curve [AUC]24h, trough [Cmin], and peak [Cmax]) plasma concentration were estimated using multiple GCV plasma concentrations from each patient. Associations between PK parameters and efficacy/safety were assessed. Of 23 patients, 20 (87.0%) exhibited an effective response. Median estimated AUC24h, Cmin, and Cmax values were 45.5 mg·h/L, 0.5 mg/L, and 6.8 mg/L, respectively. AUC24h and Cmin were not significantly associated with the efficacy of GCV (odds ratio [OR] 1.05, 95% confidence interval [CI] 0.96–1.16, p = 0.301; OR 0.92, 95% CI 0.11–7.86, p = 0.942). Cmax showed a relatively large but nonsignificant OR (OR 2.45, 95% CI 0.84–7.09, p = 0.099). No clinically relevant associations between PK parameters and safety were observed. Baseline laboratory values were associated with safety. In conclusion, no statistically significant associations were identified between GCV PK parameters and the treatment efficacy/safety of CMV infection in adult patients.
SN - 1347-5215
SN - 0918-6158
ER -